Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912455 · ClinicalTrials.gov registry record · Phase 4
CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
A Phase 4 study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT02912455 is a Phase 4 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 16 participants.
The verdict
NCT02912455, a Phase 4 study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy vs. placebo on clinical outcomes of type 2 diabetes.
Interventions
- DRUG canagliflozin
- DRUG Placebo (for canagliflozin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-01-05 |
| Est. Completion | 2018-07-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02912455
The ClinicalTrials.gov registry entry for NCT02912455 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which canagliflozin is the first listed.
NCT02912455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02912455 about?
NCT02912455 is a clinical study titled "CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes". This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy vs. placebo on clinical outcomes of type 2 diabetes.
What is the current status of trial NCT02912455?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2017-01-05. Estimated completion is 2018-07-19.
What interventions are being tested in trial NCT02912455?
The interventions under investigation include: canagliflozin (DRUG), Placebo (for canagliflozin) (DRUG).
Who is sponsoring clinical trial NCT02912455?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.